Many depressed patients who didn’t get better on one medicine were able to overcome their crushing dark spells with another, according to the largest study ever of treatments for America’s top mental-health problem.
Up to one-third of those who added or changed medicines recovered. When viewed with earlier results, the new findings mean roughly half the people who suffer from serious, long- term depression can get over it – not just improve their symptoms – with medication.
“The goal here was to find treatments that help people to get well, not just better,” said Dr. Thomas Insel, director of the National Institute of Mental Health. “We have safe and effective treatments.”
His agency paid for the $35 million study, which involved thousands of people across the U.S. and has been widely praised as a real-world test of popular drugs that have received only limited testing until now.
The study found little difference among the five drugs tested – Celexa, Zoloft, Wellbutrin, Effexor and Buspar – and wasn’t designed to compare them. All proved similarly effective and relatively safe.
The clear message, doctors said, was that antidepressants should be given a 6-to-12-week chance to work and if one does not help, another should be tried.
“It’s important not to give up if the first treatment doesn’t work fully” or causes side effects, said one study leader, Dr. John Rush of the University of Texas Southwestern Medical Center in Dallas. Almost as many people were helped the second time around as the first, he said.
Two reports from the study were published today in the New England Journal of Medicine.
About 15 million Americans each year suffer depression, and it is the leading cause of disability in people ages 15 to 44. It often recurs, and doctors sometimes talk of it as an emotional cancer that, rather than cured, is put “in remission” with successful treatment.
Nearly two dozen antidepressants are on the market – 189 million prescriptions were filled last year alone – but they are controversial. Evidence on their effectiveness is limited, and the government recently ordered stronger warnings that some can worsen suicidal tendencies in teenagers in rare cases. The risk in adults is still being studied.
One study participant, Kasey Thompson, a 40-year-old medical school administrator from Fort Worth, had suffered depression for nearly 20 years despite having a good job and lots of family and friends.
Celexa helped, but she still had sleep problems and avoided friends until she added Wellbutrin.
“Piggybacking these two drugs together made a huge impact on my depression,” Thomp son said.
